Aurinia Pharmaceuticals Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aurinia Pharmaceuticals stock.
View analyst ratings for Aurinia Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Aurinia Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aurinia Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aurinia Pharmaceuticals saw a increase in short interest in May. As of May 28th, there was short interest totaling 12,830,000 shares, an increase of 27.4% from the May 13th total of 10,070,000 shares. Based on an average trading volume of 3,620,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 11.5% of the company's shares are sold short.
View Aurinia Pharmaceuticals' Short Interest.

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted its quarterly earnings results on Wednesday, May, 5th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.05. The biotechnology company earned $0.91 million during the quarter, compared to analysts' expectations of $2.30 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 34.48% and a negative net margin of 239.29%.
View Aurinia Pharmaceuticals' earnings history.

Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AUPH shares have decreased by 5.0% and is now trading at $13.40.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued 1 year price objectives for Aurinia Pharmaceuticals' shares. Their forecasts range from $23.00 to $35.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $29.60 in the next year. This suggests a possible upside of 120.9% from the stock's current price.
View analysts' price targets for Aurinia Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aurinia Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Biohaven Pharmaceutical (BHVN), Perrigo (PRGO), Sarepta Therapeutics (SRPT), I-Mab (IMAB), TG Therapeutics (TGTX), Schrödinger (SDGR), Ionis Pharmaceuticals (IONS), Legend Biotech (LEGN), Reata Pharmaceuticals (RETA), Allakos (ALLK), Apellis Pharmaceuticals (APLS), Blueprint Medicines (BPMC), Galapagos (GLPG) and Hypera (HYPMY).
View all of AUPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Orbimed Advisors LLC (4.74%), BlackRock Inc. (0.86%), Rock Springs Capital Management LP (0.61%), DG Capital Management LLC (0.46%), Blackcrane Capital LLC (0.39%) and FIL Ltd (0.37%). Company insiders that own Aurinia Pharmaceuticals stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Peter Greenleaf and Stephen P Robertson.
View institutional ownership trends for Aurinia Pharmaceuticals.

AUPH stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, D. E. Shaw & Co. Inc., Man Group plc, Allianz Asset Management GmbH, TD Asset Management Inc., Prosight Management LP, and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp.
View insider buying and selling activity for Aurinia Pharmaceuticals or view top insider-selling stocks.

AUPH stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, DG Capital Management LLC, Blackcrane Capital LLC, FIL Ltd, DnB Asset Management AS, Barclays PLC, Gabelli Funds LLC, and InterOcean Capital Group LLC. Company insiders that have bought Aurinia Pharmaceuticals stock in the last two years include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Peter Greenleaf, and Stephen P Robertson.
View insider buying and selling activity for Aurinia Pharmaceuticals or or view top insider-buying stocks.

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUPH stock can currently be purchased for approximately $13.40.

Aurinia Pharmaceuticals has a market capitalization of $1.72 billion and generates $50.12 million in revenue each year. The biotechnology company earns $-102,680,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis.

Aurinia Pharmaceuticals employs 294 workers across the globe.

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

Aurinia Pharmaceuticals is headquartered at 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected]